LINK-J＠BIO～サンディエゴからのインサイトレポート～

宇佐美 篤
株式会社東京大学エッジキャピタルパートナーズ (UTEC)　取締役・パートナー

東京大学大学院薬学系研究科にて博士号取得。2013年UTEC参画。シード/アーリーステージのベンチャー投資・経営支援業務を行う。オリシロジェノミクス㈱(Moderna, Inc.がM&A)、RegCell, Inc.など日米で7社共同創業。2023年Japan Venture Awardsベンチャーキャピタリスト奨励賞 受賞。

下田 裕和
国立研究開発法人日本医療研究開発機構（AMED）　調整役

1999年に通商産業省に入省後、IT、サイバーセキュリティ、バイオ・再生医療、ヘルスケア、サービス業等の産業推進部局を経て、2016年から2020年まで日本貿易振興機構サンフランシスコ事務所次長、World Economic Forum第4次産業革命センターフェローを兼任。帰国後、経済産業省において情報システム厚生課長、バイオ産業政策を担う生物化学産業課長を歴任し、2025年7月より現職にて研究成果の実用化、創薬エコシステムの推進等を担当。

Ken Horne
Managing Partner, AN Ventures

Ken Horne is Managing Partner of AN Ventures, a global biotech investment firm focused on identifying scientific opportunities in Japan and building them into U.S.-based companies. Ken serves on the boards of Typewriter Therapeutics, Imbria Pharmaceuticals, Capacity Bio, Pahr Therapeutics, and Ando Therapeutics.
Ken is a seasoned healthcare investor, entrepreneur, and executive with more than two decades of experience founding, scaling, and financing life sciences companies. Previously, he served as Chair of RDiscovery (Remiges Ventures). As an entrepreneur, he co-founded or led Aline Aesthetics (acquired by Allergan), Symic Bio (acquired by Nordic Bio), and Teon Therapeutics.
Earlier in his career, Ken was a founding member of TauTona Group, an early-stage life sciences venture capital fund. He began his career at The Foundry, a leading medtech incubator, and was involved in eValve (acquired by Abbott) and Cierra (acquired by Terumo).
Ken holds BS and MS degrees in Mechanical Engineering from Stanford University and is a Kauffman Fellow (Class 17), where he was the Jeff Timmons Leadership Award recipient.

John Foley
Co-Founder, CEO360

John Foley is a growth strategist, private equity operator, and co-founder of CEO360, where his mission is to help promising life sciences companies become investable. His work sits at the intersection of leadership, capital, and execution—helping CEOs bridge the gap between scientific innovation and investor confidence.

Over 30 years, including 15 years with private equity firm RLH Equity Partners, John worked alongside middle-market CEOs to accelerate growth, strengthen market positioning, modernize operations, and prepare companies for successful exits. His focus has been transforming potential into scalable enterprise value.

In 2022, John co-founded CEO360 with David H. Crean to address a challenge they repeatedly observed in life sciences: exceptional science often struggles not because of the technology, but because leadership, governance, and execution are not yet aligned with capital expectations. Through CEO360, John helps founders develop the strategic clarity, governance discipline, and investable behaviors that increase confidence among investors, partners, and stakeholders.